Catalytic inhibition of DNA topoisomerase IIα by sodium azide

被引:12
|
作者
Ju, R [1 ]
Mao, YH [1 ]
Glick, MJ [1 ]
Muller, MT [1 ]
Snyder, RD [1 ]
机构
[1] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA
关键词
azide; ICT assay; topoisomerase II alpha;
D O I
10.1016/S0378-4274(01)00328-9
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
It has been demonstrated previously that sodium azide reduces the clastogenicity of several DNA topoisomerase II (topo II) poisons in cultured mammalian cells. These studies suggested that azide may be a catalytic topo II inhibitor. Azide interferes with mitochondrial production of ATP and is also known to inhibit cellular ATPases. Since topo II requires ATP for catalytic activity (enzyme turnover), it seemed likely that interference with ATP levels or ATP catabolism was the underlying mechanism of topo II inactivation; however, this has not been examined in living cells under conditions where the endogenous topo II is active on genomic DNA. The present studies were carried out to verify that azide inhibits endogenous topo II in cells. We show that azide blocks both decatenation and relaxation activity of purified topo II in a concentration dependent manner and reduces topoII/DNA covalent complex formation in cells. From these studies, it is concluded that sodium azide catalytically inactivates topo II via an ATP-sensitive process. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 50 条
  • [1] Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha
    Bau, Jason T.
    Kurz, Ebba U.
    BIOCHEMICAL PHARMACOLOGY, 2011, 81 (03) : 345 - 354
  • [2] Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair
    Saleh, Ekram M.
    TUMOR BIOLOGY, 2015, 36 (11) : 8985 - 8992
  • [3] Expression of DNA topoisomerase IIα in oligodendroglioma
    Bredel, M
    Gatterbauer, B
    Birner, P
    Haberler, C
    Ströbel, T
    Budka, H
    Rössler, K
    Hainfellner, JA
    ANTICANCER RESEARCH, 2002, 22 (2B) : 1301 - 1304
  • [4] Expression of DNA topoisomerase IIα in thyroid neoplasia
    Lee, A
    LiVolsi, VA
    Baloch, ZW
    MODERN PATHOLOGY, 2000, 13 (04) : 396 - 400
  • [5] Regulation of catalytic activity and nucleolar localization of rat DNA topoisomerase IIα through its C-terminal domain
    Yasuda, Kazushi
    Kato, Yuri
    Ikeda, Shogo
    Kawano, Shinji
    GENES & GENETIC SYSTEMS, 2020, 95 (06) : 291 - 302
  • [6] Mutagenesis of Intrinsically Disordered Domain Impacts Topoisomerase IIα Catalytic Activity
    Chang, Jeong Won
    O'Brian, Addison K.
    Thomas, Allison J.
    Hardin, Mattalyn R.
    Latham, Brooke D.
    Ngabonziza, Daniel
    Simpson, Lily G.
    Wade, Benjamin D.
    Kuhnhenrich, Laura
    Thompson, Nina M.
    Endsley, Clark E.
    Deweese, Joseph E.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (08)
  • [7] DNA topoisomerase IIα expression in optic pathway gliornas of childhood
    Bredel, M
    Slavc, I
    Birner, P
    Czech, T
    Haberler, C
    Ströbel, T
    Wolfsberger, S
    Budka, H
    Hainfellner, JA
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (03) : 393 - 400
  • [8] The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα
    Yalowich, Jack C.
    Wu, Xing
    Zhang, Rui
    Kanagasabai, Ragu
    Hornbaker, Marisa
    Hasinoff, Brian B.
    BIOCHEMICAL PHARMACOLOGY, 2012, 84 (01) : 52 - 58
  • [9] Proteasomal inhibition stabilizes topoisomerase IIα protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide)
    Congdon, Lauren M.
    Pourpak, Alan
    Escalante, Aluvia M.
    Dorr, Robert T.
    Landowski, Terry H.
    BIOCHEMICAL PHARMACOLOGY, 2008, 75 (04) : 883 - 890
  • [10] DNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer
    MacGrogan, G
    Rudolph, P
    de Mascarel, I
    Mauriac, L
    Durand, M
    Avril, A
    Dilhuydy, JM
    Robert, J
    Mathoulin-Pélissier, S
    Picot, V
    Floquet, A
    Sierankowski, G
    Coindre, JM
    BRITISH JOURNAL OF CANCER, 2003, 89 (04) : 666 - 671